Investing.com -- Medtronic plc reported third-quarter fiscal 2025 earnings that beat analyst estimates, while revenue fell short of expectations. The medical device maker reiterated its full-year guidance as it sees continued strength in key segments.
Medtronic (NYSE:MDT) posted adjusted earnings per share of $1.39 for the quarter ended January 24, 2025, surpassing the analyst consensus of $1.36. Revenue came in at $8.29 billion, slightly below the $8.33 billion analysts had forecast. The company's stock edged down 0.33% following the results.
Revenue grew 2.5% year-over-year, as reported, and 4.1% on an organic basis. The Cardiovascular portfolio saw 5% organic growth, driven by strong performance in cardiac ablation solutions and structural heart products. The Neuroscience segment posted 5.2% organic growth, with double-digit increases in neuromodulation.
"We delivered strong earnings this quarter, with significant improvements in both our gross margin and operating margin on the back of our ninth quarter in a row of mid-single digit organic revenue growth," said Geoff Martha, Medtronic chairman and CEO.
The company's Diabetes segment showed notable improvement, with revenue increasing 10.4% organically. This was attributed to the continued adoption of the MiniMed 780G automated insulin delivery system in the U.S. and increasing continuous glucose monitoring attachment rates internationally.
Medtronic reiterated its fiscal 2025 guidance, expecting organic revenue growth of 4.75% to 5% and adjusted EPS between $5.44 and $5.50. This outlook aligns with the current analyst consensus of $5.45 per share.
The company highlighted progress in key growth areas, including the rapid adoption of its pulsed field ablation systems and the expected Medicare coverage for renal denervation in treating hypertension by October 2025.
Related Articles
Medtronic Q3 earnings beat estimates, revenue misses
Ugandan army enters eastern Congolese city to halt militia violence
U.S. paper industry urges Trump to negotiate deforestation-free status with EU
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。